SHARE ID™ (Sharing Hospital data to Advance Research and Enhance patient care in Infectious Diseases) is a collaborative research consortium dedicated to optimizing the treatment and management of patients with serious infections resulting from antibiotic‑resistant pathogens. The goal of SHARE ID is to accelerate efforts to address antibiotic‑resistant pathogens by building a robust and collaborative research platform for the infectious diseases community.
SHARE ID is comprised of multiple hospitals and health systems, and is designed to allow for secure and HIPAA‑compliant aggregation of hospital- and patient-level data. Its mission is to leverage real‑world data from participating institutions and innovative analytics to identify the burden of illness, conduct comparative effectiveness research, spread awareness, and develop decision support tools to assist healthcare decision makers in treating patients with serious infections due to antibiotic‑resistant pathogens.
SHARE ID is designed to enable the infectious diseases community to more rapidly understand and respond to the burdens and risks associated with antibiotic‑resistant infections. This involves actively pursuing scientific questions of interest, informing antibiotic stewardship, and promoting awareness about critical infectious diseases issues. SHARE ID will provide members with the data and evidence needed to inform clinical practices and policies at their institutions.
SHARE ID is led by a multidisciplinary steering committee including infectious diseases experts, hospital epidemiologists, data analytics experts, statisticians, and industry representatives with relevant expertise.
SHARE ID promotes active collaboration with infectious diseases colleagues through a membership program.
Establish a validated, secure information‑sharing platform to merge patient‑level data from multiple partner hospitals and healthcare systems.
Leverage real‑world data across participating institutions with innovative analytical methods to define the burden, risk factors, and optimal treatment approaches for patients with antibiotic‑resistant infections.
Provide members with actionable data to improve patient care, including benchmarking and comparative effectiveness analyses, based upon outcomes analysis and epidemiology at both national and local levels, and patient risk factors.
Increase clinical awareness of illness burdens and unmet medical needs resulting from multidrug‑resistant infections through dissemination of research findings and engagement and education of infectious diseases clinicians, particularly at regional and institutional levels.
The vision of SHARE ID is to improve patient outcomes, reduce antimicrobial resistance, and decrease the spread of antibiotic‑resistant pathogens.
This is an ambitious vision and one that will require an extended time frame and concerted effort on the part of a broad contingency of contributing participants. But it is one that we believe is possible, through the development and distribution of resources and insights that SHARE ID will help effect.
The values that SHARE ID considers its core drivers include the following, which will be more fully defined as the Steering Committee discusses and reaches consensus on members’ priorities.
To learn more about becoming a SHARE ID data contributing site, please contact:
Dr. Thomas Lodise is an Associate Professor at Albany College of Pharmacy and Health Sciences (ACPHS), Albany, New York and is an infectious diseases clinical pharmacist at the Stratton VA Medical Center, Albany, New York.
Integrating his dual interests in scholarship and patient care, his overall research goal is to quantitatively enhance our current understanding of antimicrobial exposure‑response relationships in patients with invasive bacterial infections. His specific research objectives are 3‑fold: develop "personalized" patient care strategies that improve outcomes, reduce the likelihood of toxicity, and minimize the emergence of antibiotic resistance. Research cannot improve patient care unless the knowledge is transferable. To this end, he employs cutting‑edge mathematical modeling techniques to optimize process‑of‑care variables, such as empirical antibiotic selection, time to appropriate antibiotic delivery, and intensity and duration of antibiotic therapy.
Dr. Lodise is currently implementing epidemiological and outcomes research proposals at several institutions in the Albany, New York area, including the Albany Medical Center Hospital and Stratton VA Medical Center. He is also actively involved in Phase III and IV clinical trial research centered on improving the outcomes of patients with antibiotic‑resistant infections. He has published over 90 peer‑reviewed articles in reputable scientific journals, including Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy, Lancet Infectious Diseases, Chest, and Journal of Antimicrobial Chemotherapy. He is on the editorial boards for Antimicrobial Agents and Chemotherapy, Pharmacotherapy, and Diagnostic Microbiology and Infectious Diseases.
Dr. Lodise is a paid consultant of Actavis and is being provided funding from Actavis in exchange for his participation as a SHARE ID™ steering committee member.
James A. McKinnell, MD (Jamie) is an infectious diseases specialist with specific research interests related to clinical management and prevention of hospital‑associated infections, particularly infections related to vancomycin‑resistant enterococcus (VRE) and, more recently, methicillin‑resistant Staphylococcus aureus (MRSA).
It should be noted that utilizing existing clinical datasets to answer clinically important questions has been an ongoing theme for Dr. McKinnell. While in fellowship, Dr. McKinnell published his earliest manuscripts using data from the prospective observational cohort of the outpatient HIV clinic at the University of Alabama at Birmingham. Subsequently, he developed a data extraction system from the University of Alabama Medical Center that resulted in additional publications. His more recent work has focused on utilizing clinical data from the Ronald Reagan Medical Center at the University of California, Los Angeles and Torrance Memorial Medical Center in Torrance, California.
For Dr. McKinnell, development of a research database that collects data from multiple centers would be a logical and powerful extension from his previous research experiences. The multi‑center research database that will emerge from this project will provide a rich source of generalizable data that will prove invaluable for future research. The project provides an unrivaled opportunity to conduct comparative effectiveness studies, economic impact modeling, and detailed hospital epidemiology investigations.
Dr. McKinnell is being provided funding from Actavis in exchange for his participation as a SHARE ID™ steering committee member.
Dr Abdulrahman M. El‑Sayed is a Population Health Scientist and Assistant Professor in the Department of Epidemiology at Columbia University, where he directs the Columbia University Systems Science Program and co‑directs the Global Research Analytics in Population Health initiative. His research considers the intersections between society and health, health disparities, and the uses of simulation modeling in epidemiology. He has authored over 40 peer‑reviewed scientific articles, commentaries and book chapters, and has been featured at national and international conferences.
In addition, he is a Fellow at Demos, a non‑profit policy center based in New York. His commentary engages the public debate about health policy issues in the United States and globally, with a particular focus on disease prevention in light of epidemiologic trends and emerging public health challenges. His commentary has been published in The New York Times, The Guardian, Al Jazeera, Project Syndicate, CNN, and the Huffington Post, among other venues. He is an Associate Editor at The 2x2 Project — a media venue dedicated to translating public health science to the broader public sponsored by Columbia's Department of Epidemiology. He also appears regularly as a health commentator on a number of television channels, including Al Jazeera America, NBC News, HuffPost Live, and others.
Dr. Lautenbach is a Professor of Medicine and Epidemiology. He is also a Senior Scholar at the Center for Clinical Epidemiology and Biostatistics (CCEB), Senior Fellow at the Leonard Davis Institute for Health Economics, Senior Fellow at the Center for Public Health Initiatives, and Fellow in the Institute on Aging, all at the University of Pennsylvania. Dr. Lautenbach is the Associate Director of the Clinical Epidemiology Unit (CCEB) for Educational Programs and the Associate Hospital Epidemiologist at the Hospital of the University of Pennsylvania. His research focuses on healthcare‑acquired infections and antimicrobial resistance in healthcare and community settings. He is particularly interested in the relationship between patterns of antibiotic utilization and antimicrobial resistance as well as the impact of antibiotic resistance on clinical and economic outcomes. Dr. Lautenbach is an Associate Editor for Infection Control and Hospital Epidemiology.
Dr. Lautenbach is being provided funding from Actavis in exchange for his participation as a SHARE ID™ steering committee member.
Michael D. (Mick) Murray, PharmD, MPH, FISPE, is Director of Regenstrief Institute's Data Core and Executive Director, Regenstrief Center for Healthcare Effectiveness Research. He is a faculty member at the Purdue University College of Pharmacy where he is Distinguished Professor of Pharmacy and Endowed Chair of Medication Safety and an Adjunct Professor of Medicine in the Division of General Internal Medicine and Geriatrics at the Indiana University School of Medicine. He is a member of the Institute of Medicine's Clinical Effectiveness Research Innovation Collaborative (CERIC).
Mick is in his second term of appointments at Purdue, Indiana and Regenstrief Institute. He was a faculty member at Purdue's College of Pharmacy from 1977 to 2004. He took a brief hiatus from 2004 to 2010 to become the Mescal S. Ferguson Distinguished Professor and Chair of Pharmaceutical Outcomes and Policy at the University of North Carolina at Chapel Hill.
Mick's research interests include developing pharmacy services to improve drug therapy in older adults with chronic disorders, medication safety, improving the quality of health of low‑income minority people, and pharmacoepidemiology using large population computer databases. He is a Fellow of the International Society for Pharmacoepidemiology and has worked closely with Regenstrief Institute's data core and investigators for many years.
Dr. Murray is being provided funding from Actavis in exchange for his participation as a SHARE ID™ steering committee member.
Shailja is an accomplished healthcare executive and has 15+ years of industry experience. She has served in a variety of leadership roles and has a 360‑degree understanding of the healthcare industry, having worked in different industries within healthcare. In her current role, she is responsible for leading the Global Health Economic & Outcomes team at Actavis across the entire portfolio. She has been instrumental in laying the foundation for a new HEOR & Value model, collaborative research with academia and stakeholder engagement strategies. Shailja has led successful global launches and has led the teams responsible for "end to end" evidence development to support market access and reimbursement. She has authored many scholarly papers and presentations for the world's leading journals and societies in the areas of real-world evidence, patient access, and informatics.
Shailja has also worked in the device industry (GE Healthcare) and was responsible for providing the medical strategy for "incubation" projects. She has presented at multiple conferences and holds patents for her work.
Dr. Dixit is an employee of Actavis. Dr. Dixit is also a shareholder of Actavis plc.
Stan is one of America's distinguished scholars in healthcare information policy and management, having taught e-health and healthcare e-business for nearly 20 years. He has authored over 100 scholarly papers and presentations for the world's leading journals and societies in healthcare technology management, informatics, and e‑governance. In 1996, he was elected to the United States‑based College of Healthcare Information Management Executives. In 2003, he was elected as a Fellow in the Royal Society of Medicine in the United Kingdom for his research with the National Health Service in using handhelds to track patient data. Stan is currently a Visiting Professor at the Indian Institute of Technology, New Delhi, India, while also overseeing all programmatic activities at HITLAB.
Stan Kachnowski is an employee of HITLAB. HITLAB is paid service provider of Actavis and is receiving direct funding from Actavis in exchange for the services being performed by HITLAB in connection with the SHARE ID™ program.
In 2014, Actavis, a leading global specialty pharmaceutical company, launched and funded SHARE ID along with HITLAB, a healthcare innovation and teaching laboratory, and a team of Infectious Diseases experts. SHARE ID is a collaborative research consortium designed to offer a platform for scientists, clinicians, hospitals, and infectious diseases experts to expedite the development of scientific innovations, optimal treatment pathways, and antibiotic stewardship.
The consortium’s initial focus will be on multidrug‑resistant Gram‑negative infections.
Actavis plc provides support to SHARE ID based on its shared commitment to address challenges associated with antimicrobial drug resistance and to focus on enhancing patient care and outcomes in areas of greatest medical unmet need. SHARE ID will provide a better understanding of persistent unmet needs in the treatment of serious infectious diseases and help find and advance healthcare solutions to address this problem.